Lecture Notes on Nucleotide Metabolism, DNA Replication, Transcription, and Translation

ADA deficiency and purine metabolism

  • ADA deficiency leads to accumulation of deoxyadenosine and its triphosphate form, causing lymphotoxicity and impaired immune function.
  • Immune implications: reduces the ability to fight infections due to dysfunctional lymphocytes.
  • Therapeutic approaches for ADA deficiency:
    • Gene therapy: patient cells (lymphocytes) are transfected with a vector carrying a working ADA gene, then transfused back into the patient.
    • Rationale: restore functional ADA enzyme to degrade toxic nucleotides.
  • Glucose-6-phosphate pathway and uric acid link:
    • One pathway ends in uric acid production; there are choke points where enzyme activity can drive overproduction of uric acid.
    • Excess uric acid has low water solubility, leading to poor excretion and deposition in joints (gout).

Gout, uric acid, and therapy

  • Uric acid overproduction -> urate crystallization and deposition in joints, most famously the big toe, causing inflammation and severe pain (gout).
  • Treatments to reduce uric acid:
    • Xanthine oxidase inhibitors (e.g., allopurinol) mimic hypoxanthine to inhibit conversion to uric acid; results in more soluble precursors that are excreted.
    • Probenecid: increases renal clearance of uric acid.
  • Allopurinol mechanism: inhibits the final choke point before uric acid production; formed urate precursors are more soluble and excretable.
  • Drug concept: many gout drugs mimic naturally occurring molecules to interfere with metabolic steps.

Purine salvage and nucleotide targets

  • Salvage pathway overview:
    • A repair/recycling pathway; humans recycle a large fraction of purines to conserve resources.
    • About 90% of all purines are salvaged by cells.
  • Nucleotides as drug targets:
    • Enzymes and coenzymes involved in nucleotide metabolism (dehydrogenases, kinases, ATPases, ligases) are druggable targets.
    • GPCRs are major drug targets; more than 50% of approved drugs target GPCRs; current estimates suggest up to 80% of drugs may affect nucleotide signaling or related second messenger systems (e.g., cAMP).
    • Second messenger systems under GPCR control (e.g., cyclic AMP) are common drug action pathways.
  • Nucleotides in medicinal chemistry:
    • Nucleoside/nucleotide metabolism and signaling are central to many drugs, especially in oncology and infectious disease.
    • Future drugs increasingly target nucleic acids or nucleotide-processing enzymes.
  • Antiviral and anticancer examples (nucleotide/nucleoside analogs):
    • Acyclovir (guanosine analog) and other nucleoside analogs disrupt viral DNA synthesis.
    • 5-Fluorouracil (a pyrimidine analog) and capecitabine are used in cancer therapy as antimetabolites.
    • Salvage pathways and nucleotidyl transferases are targeted in various cancer and antiviral strategies.
  • Enzyme roles in nucleotide metabolism:
    • Coenzyme synthesis and function (e.g., FAD cannot be synthesized de novo by humans; must be supplied by diet and metabolism).
    • Nucleotides serve as substrates, cofactors, or enzyme components; many druggable enzymes include dehydrogenases, kinases, ATPases, ligases, and proteases that utilize ATP or nucleotide moieties.
  • GPCRs and drug discovery:
    • GPCR targeting is central to many drugs; signaling through second messengers (like cAMP) is a common mechanism.
    • Kinases are a major class of drug targets; dozens of kinase inhibitors exist for cancer therapy.
    • Two main binding-pocket strategies for kinase inhibitors:
    • ATP-binding pocket inhibitors (block ATP access to the kinase).
    • Allosteric/inexact binding pocket inhibitors (target non-ATP sites).
  • Kinase inhibitors and drug discovery examples:
    • Dozens of kinase inhibitors exist for cancer; some examples extend to other indications (off-label use or trials).
    • Nilotinib has been explored in Alzheimer's disease in clinical trials.
  • Topoisomerases, DNA damage, and drugs:
    • Topoisomerases relieve torsional strain during replication and transcription; inhibitors can act as either poisons or inhibitors.
    • Etoposide is described as a topoisomerase poison (not a traditional enzyme inhibitor) that traps the enzyme-DNA complex.
    • Doxorubicin intercalates into DNA and indirectly traps topoisomerase, acting as a topoisomerase poison rather than a direct inhibitor.
    • Distinction: inhibitors directly block enzyme activity; poisons trap the enzyme-DNA complex via DNA intercalation or other means.
  • Acute example pathways and drugs:
    • Etoposide (topoisomerase poison) vs topoisomerase inhibitors.
    • Doxorubicin (DNA intercalator; acts as a poison to topoisomerase rather than a direct inhibitor).

DNA replication: structure, origin, and fidelity

  • DNA structure and packaging:
    • Human genome length ~2 meters; nucleus diameter is small; DNA is organized into chromatin (DNA + histones + nonhistone proteins).
    • Chromosome: two copies (sister chromatids) held together at the centromere.
    • Genes: DNA segments encoding functional RNA or protein products.
    • Nucleosome: basic unit of chromatin; DNA wrapped around a core of histones (four types of histones); ~30,000,000 nucleosomes in a human cell.
  • Prokaryotic vs eukaryotic gene organization:
    • Prokaryotic genes have coding regions with stop codons and translated regions but generally lack introns.
    • Eukaryotic genes contain introns (noncoding) in addition to exons.
  • DNA replication overview:
    • Three main stages: initiation, elongation, termination.
    • Initiation: formation of initiation complex; promoter access to DNA.
    • Elongation: synthesis of leading and lagging strands; leading strand synthesized continuously; lagging strand synthesized in Okazaki fragments.
    • Termination: completion of synthesis; no formal substeps beyond end of process.
  • Replication machinery and roles:
    • Helicase: unwinds the DNA double helix by breaking hydrogen bonds.
    • Topoisomerase: relieves supercoiling by cutting one or both DNA strands (Topoisomerase I cuts one strand; Topoisomerase II cuts both strands).
    • Single-stranded DNA binding protein (SSB): stabilizes separated strands.
    • Primase: synthesizes RNA primers to provide starting points for DNA synthesis.
    • DNA polymerases: synthesize new DNA strands in the 5'→3' direction; include specialized polymerases in eukaryotes (e.g., polymerase alpha with primase as a subunit) and others like delta and epsilon for elongation.
    • RNA primers removed by exonuclease; gaps filled by DNA polymerase; fragments joined by ligase.
  • Semiconservative replication:
    • Each daughter DNA molecule contains one old (template) strand and one newly synthesized strand.
  • Origins of replication:
    • Prokaryotes: single origin per circular chromosome.
    • Eukaryotes: multiple origins to increase efficiency.
    • AT-rich regions (two hydrogen bonds) are common origin features.
  • Replication fidelity:
    • DNA polymerase proofreading reduces errors dramatically; mismatch occurs ~1 per 10^5–10^6 bases without proofreading.
    • With proofreading, error rate can be as low as ~1 in 10^8 bases for DNA polymerase III.
    • Mutations contribute to aging and disease; fidelity is a foundational principle of genetic stability.
  • Telomeres and the end-replication problem:
    • Linear chromosomes face end replication problems because DNA polymerase cannot fully replicate the very ends of the lagging strand.
    • Telomeres: G-rich repeats at chromosome ends; telomerase extends the parental strand using an RNA template within the enzyme, adding repeats to compensate for end-replication loss.
    • Lagging strand completion involves DNA polymerase alpha and primase after telomere extension.
    • Telomere biology links to aging (senescence when telomeres shorten) and cancer (telomerase often overexpressed in cancer cells).
    • Drug context: as of early 2022, there were no approved telomerase-targeting drugs; later updates indicate ongoing trials with near-term potential.

Transcription and RNA processing

  • Transcription basics:
    • RNA polymerase catalyzes RNA synthesis from a DNA template to produce pre-mRNA in eukaryotes.
    • Three main RNA types in transcription: rRNA (ribosomal RNA), tRNA (transfer RNA), and mRNA (messenger RNA).
    • Multiple RNA polymerases in eukaryotes (RNA Pol I, II, III); bacteria have a single RNA polymerase.
  • Gene organization and regulation:
    • Regulatory sequences (e.g., TATA box) and upstream elements influence transcription initiation.
    • Transcription factors (e.g., TBP in TATA-binding protein, TFIID, TFIIH) help form the initiation complex and access DNA.
    • Initiation complex formation involves promoter opening and RNA polymerase recruitment.
  • Transcriptional stages:
    • Initiation: promoter recognition, melt of DNA, start of RNA synthesis with 5' cap formation later.
    • Elongation: RNA chain lengthens; processivity factors ensure efficient transcription.
    • Termination: transcription ends; polyadenylation signals are recognized; pre-mRNA is formed.
  • 5' capping and 3' polyadenylation:
    • 5' cap added for mRNA stability; 3' poly-A tail added to protect against nucleases.
  • RNA maturation and splicing:
    • Splicing/removal of introns occurs in eukaryotes (not in prokaryotes).
    • Spliceosome recognizes conserved sequences at intron boundaries (e.g., GU at 5' splice site and AG at 3' splice site); introns removed; exons joined.
    • Mutations in splice sites can lead to disease (e.g., thalassemia caused by mis-splicing).

Translation and the genetic code

  • Translation overview:
    • Translation occurs on ribosomes (composed of a small and a large subunit) and uses mRNA as a template to synthesize protein.
    • Ribosome components include ribosomal RNA (rRNA) and many proteins.
  • Genetic code properties (to be on the exam):
    • Triplet code: amino acids are encoded by codons consisting of three nucleotides.
    • Degeneracy (redundancy): 64 codons code for 20 amino acids; multiple codons can code for the same amino acid.
    • Nonoverlapping: adjacent codons do not overlap.
    • Universality: codons encode the same amino acids across life forms.
    • Directionality: code read in a fixed 5'→3' direction.
    • Start codon: AUG, typically codes for methionine (Met) in eukaryotes; in bacteria and mitochondria, methionine is also the initiating amino acid.
    • Stop codons: UAA, UAG, UGA terminate translation; do not code for amino acids.
  • Translation initiation and elongation:
    • Initiation: initiation factors assemble with the small ribosomal subunit; initiator tRNA (charged with methionine) binds to the start codon on mRNA; large subunit joins to form the full ribosome.
    • tRNA binding sites: E (exit), P (peptidyl), A (aminoacyl).
    • Initiation codon sets the reading frame; first amino acid incorporation occurs at the P site.
    • Elongation: successive aminoacyl-tRNA enters the A site, peptidyl transferase forms a peptide bond, ribosome translocates; methionine is typically released as translation proceeds.
    • Termination: a stop codon is recognized by release factors; polypeptide released; ribosomal subunits dissociate.
  • Practical context and exam focus:
    • Concepts to understand: codon-anticodon pairing, reading frame maintenance, and consequences of frame shifts.
    • Examples and clinical relevance may include mis-splicing, codon mutations, and translation inhibitors.

Connections, implications, and exam strategy

  • Connections to foundational principles:
    • Structure-function relationships: chromatin packing affects gene expression; DNA replication fidelity underpins genetic stability; telomeres influence aging and cancer dynamics.
    • Central dogma: DNA → RNA → protein, with regulation at transcription and translation steps.
    • Pharmacology and therapeutics: many drugs target nucleotide metabolism, DNA replication, transcription, translation, or signaling pathways (GPCRs, kinases, topoisomerases).
  • Real-world relevance:
    • ADA deficiency and gene therapy illustrate translational medicine and personalized therapy approaches.
    • Gout illustrates metabolic disease management and the impact of solubility and excretion on treatment strategies.
    • Telomerase biology bridges aging research and oncology (cancer cells often upregulate telomerase).
  • Quiz and exam strategy (as communicated in the lecture):
    • The quiz covers today’s lectures and the first two chapters: genes and chromosomes, nucleotides, and nucleic acids; additional material to be reviewed later in the course.
    • Resources: ExamSoft quizzes; Canvas slides; exam reviews in upcoming sessions.

Key numerical and factual references to remember

  • Gout pathophysiology: uric acid deposits in joints due to low solubility in water.
  • Salvage pathways: approximately 90% of purines are salvaged by cells.
  • DNA replication fidelity: typical mismatch rate without proofreading is ~1 in 10^5–10^6 bases; with proofreading, the rate can be as low as ~1 in 10^8 bases for high-fidelity polymerases.
  • Chromatin packaging: ~30,000,000 nucleosomes in a human cell.
  • GPCR drug targeting: historically >50% of approved drugs target GPCRs; estimates suggest up to ~80% of drugs have effects linked to nucleotide signaling or second messengers.
  • Genetic code basics: 64 codons encode 20 amino acids; start codon AUG; stop codons UAA, UAG, UGA.
  • DNA replication polarity: leading strand grows 5'→3' continuously; lagging strand grows 5'→3' in Okazaki fragments; synthesis occurs in the 5'→3' direction on both strands.
  • Telomere biology: telomerase extends chromosome ends to compensate for end-replication problems; telomere shortening is associated with aging; telomerase overexpression is common in cancer cells.
  • Topoisomerases: type I cuts one strand; type II cuts both strands to remove supercoils; drugs can act as poisons or inhibitors depending on their mechanism.
  • Transcription and translation basics:
    • Initiation, elongation, termination; 5' capping and 3' poly-A tail stabilize mRNA; splicing removes introns (present in eukaryotes only).
    • Ribosome functional sites (A, P, E) and the roles of tRNA and rRNA in decoding and peptide bond formation.

Note

  • The content above reflects the material presented in the transcript and emphasizes exam-relevant concepts, drug mechanisms, and fundamental molecular biology processes as discussed. For any future exam prep, refer to the Canvas slides and the upcoming exam review session announcements (e.g., Zoom link for review).